Who Manufactures Semaglutide: The Practical Version

what may a supplement legally claim here?

A supplement cannot claim to be semaglutide, replace semaglutide, work like semaglutide, or relieve semaglutide side effects without moving toward a drug claim. Semaglutide is not a supplement ingredient; it is a prescription-drug active ingredient in FDA-approved GLP-1 drugs, and 21 CFR 101.93(g)(2) makes substitute-for-therapy and drug-augmentation positioning disease-claim territory. If your offer is a capsule, gummy, powder, or dropper bottle, the legal ceiling is structure/function language such as appetite, metabolism, or normal glucose support, with substantiation, not GLP-1 equivalence.

FDA's concern is not the label alone. Under 21 CFR 201.128, intended use can be shown by claims, advertising matter, written statements, oral statements, or distribution circumstances, so the VSL, quiz, advertorial, cart page, emails, and bundle all matter. FDA said this directly in its Gram Peptides letter: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,'" the website evidence still established human-drug intent. That sentence is why research-use-only copy is not a shield.

The DSHEA disclaimer, meaning the required supplement disclaimer, only belongs on lawful structure/function claims. It doesn't repair a disease claim. FTC's 2022 guidance makes the same point from the advertising side: a disclaimer that is "directly contradictory and ineffective to negate the acne treatment claim" does not cure the express claim. We checked this because GLP-1-adjacent offers often paste disclaimer language into funnels and then keep the same comparative hook.

The practical copy line is narrow: say what the supplement supports in normal physiology, define the population honestly, and keep the GLP-1 drug names out of the claim path. That includes negative positioning. "Natural Ozempic" is not clever positioning; it is an admission that the offer wants prescription-drug authority without prescription-drug status.

• Use structure/function claims only: support, maintain, or help normal functions, with the DSHEA disclaimer where required.
• Do not say the supplement is semaglutide, generic semaglutide, GLP-1, Ozempic-like, Wegovy-like, or a replacement for a prescription drug.
• Do not target side effects of GLP-1 therapy, because 21 CFR 101.93(g)(2)(ix) reaches therapy-related adverse-event claims when the adverse events are diseases.
• Do not treat research-use-only labeling as a compliance strategy if the page, dosing, bundle, or checkout tells a human-use story.

who is the buyer, really?

The buyer is usually not asking a chemistry question; they are trying to decide whether the bottle, vial, clinic, or VSL is legitimate enough to buy or promote. That distinction matters. Someone searching who manufactures semaglutide may be a patient, an affiliate, a media buyer, a med-spa operator, or a supplement founder watching GLP-1 demand spill into direct response.

We could not verify the upstream active pharmaceutical ingredient supply chain for every FDA-approved semaglutide product from the fact pack; a current FDA label, Orange Book entry, or manufacturer regulatory filing would settle that specific manufacturing chain. What we can say from the provided record is narrower and more useful for advertising: FDA-approved semaglutide products and unapproved compounded or research-grade versions are not interchangeable advertising objects.

Your buyer hears "semaglutide" as an outcome shortcut: appetite reduction, weight loss, injection, prescription, and medical authority all compressed into one word. That is exactly why supplement funnels get into trouble. If the ad borrows the drug's reputation, the platform and regulator do not need the bottle to contain semaglutide before they treat the claim as drug-adjacent.

For audience research, the useful comparator is not a generic supplement buyer. Use competitor ad intelligence to separate prescription-drug telehealth funnels, compounded GLP-1 funnels, research-peptide sellers, and supplement offers that merely draft off GLP-1 demand. They may target the same anxiety, but they do not carry the same legal permission.

what does the enforcement record show?

The enforcement record shows FDA is treating GLP-1 and research-peptide marketing as an active priority, not a theoretical compliance issue. FDA's warning-letter database contained 139 letters mentioning semaglutide in 2024-2026 as of July 30, 2026, with coordinated telehealth sweeps and peptide-seller letters. We counted that record because the volume changes the risk calculation: this is not a dead corner of health advertising.

FDA's March 31, 2026 Gram Peptides letter is the cleanest example for operators. FDA cited retatrutide and tirzepatide product-page copy, not just the vial label, and held that human-use intent overrode research-use-only statements. In the same letter, FDA treated bacteriostatic water sold with injectable peptides as evidence because "the sale of these products together demonstrates that you intend for your 'Bacteriostatic Water for Injection' to be used in combination for injection." Bundles speak.

The GLP-1 compounding record is just as direct. FDA determined the tirzepatide injection shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025; the enforcement-discretion wind-down dates for copying those drugs have now lapsed. FDA also said semaglutide and tirzepatide do not currently appear on the 503B bulks list or FDA's drug shortage list, per FDA's GLP-1 compounding update.

FTC is not absent. Its health-products guidance says "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing," and weight-loss promises still run into Gut Check, endorsements, reviews, and negative-option enforcement. A semaglutide-adjacent funnel with fake reviews, hidden continuity, or exaggerated VSL claims has more than one regulator waiting for it.

• FDA warning-letter theory: intended use beats labels and disclaimers.
• FTC theory: health claims need competent and reliable scientific evidence, usually human RCTs.
• Platform theory: prescription-drug and unreliable-claim policies can block the ad before FDA acts.
• State theory: attorneys general and medical boards are moving against research-grade peptide use in clinics.

what does the product actually cost to make?

The product cost depends first on whether you mean an FDA-approved injectable drug, a compounded drug, a research peptide, or a supplement drafted around the same demand. The fact pack gives usable manufacturing economics for supplements, not a lawful cost model for copying semaglutide. That is the right split: your supplement COGS can be modeled, but it does not answer whether the GLP-1 comparison can run.

For ordinary supplement offers, published private-label economics are far below the retail prices VSLs often need to support media buying. SMP Nutra publishes stock private-label supplements at $4-$20 per unit and custom formulations at $5-$30 per unit at 2,500-5,000 bottles per SKU, excluding shipping. Inventory Ready's published ranges put a 60-count capsule bottle around $2.50-$5.00 at roughly 5,000-unit runs, but those figures are marked likely, so we treat them as directional.

Testing, packaging, freight, fulfillment, returns, chargebacks, and ad waste are what turn a cheap bottle into a hard business. Medallion Labs lists $164 per sample for a bundled 4-metal heavy-metals package and $149 for a five-organism micro panel; Fulfyld publishes an average all-in fulfillment cost of $7.51 for a 4-12 oz package on standard 2-5 day shipping. Those numbers are specific vendors, not industry law, but they are good enough to stop fantasy margins.

If you are comparing a supplement SKU to a telehealth GLP-1 funnel, compare the whole machine, not the molecule. Telehealth has prescriber, lab, pharmacy, certification, cancellation, and prescription-drug advertising constraints. A supplement has lower product cost, but it loses the right to say the thing that created the demand.

what does the competition already run?

The competition runs four different stories under one demand cloud: approved GLP-1 access, compounded GLP-1 access, research-peptide availability, and supplement alternatives that imply the same outcome without saying the drug name. They look similar in a swipe file, but they are not equivalent compliance assets. We changed our view on this after reading the FDA peptide letters: the bundle and the surrounding page can classify the offer even when the headline stays cautious.

The visible pattern in supplement land is displacement. The page does not say it manufactures semaglutide; it says insulin, appetite, metabolism, or a "GLP-1 pathway" explains stubborn weight, then sells a capsule as the operator's softer answer. That may avoid an explicit prescription-drug claim, but it can still create an implied disease or drug-comparison claim when the images, testimonials, and VSL sequence complete the thought.

Use an ad library tool to classify the offer type before you borrow a hook. A telehealth ad that can lawfully discuss prescription access may be useless precedent for a supplement advertiser. A peptide seller running today may be surviving review lag, not proving the claim is permitted. The fact that a competitor's ad is live is evidence of ad delivery, not evidence of legal clearance.

Cloaking makes this niche look cleaner than it is. Meta has sued advertisers over ad-review evasion, Google suspends for circumventing systems without prior warning, and FDA treats websites, marketplace listings, and social pages as intended-use evidence. If the offer depends on showing one story to review and another to buyers, read where cloakers come from before you mistake evasion for market validation.

• Approved-drug telehealth: prescription-drug rules, certification, sourcing, and medical supervision issues.
• Compounded GLP-1: shortage-delisting and essentially-a-copy problems after FDA's wind-down dates.
• Research peptides: research-use-only labels do not control intended use when the page markets human outcomes.
• Supplements: lower product cost, but no right to claim semaglutide equivalence.

where does the claim ceiling bite hardest?

The ceiling bites hardest at comparison claims, not at generic wellness language. A capsule can talk about supporting normal metabolism if it has substantiation and avoids disease context; it cannot credibly live next to Ozempic, Wegovy, Mounjaro, Zepbound, semaglutide, or tirzepatide language and still pretend the drug comparison is not doing the selling.

Google's policy is especially direct on the supplement version of this move. Under its Unapproved substances policy, Google bans products that imply they are as effective as prescription drugs regardless of legality, and its prescription-drug reference list includes semaglutide, tirzepatide, liraglutide, Ozempic, Wegovy, Mounjaro, and Zepbound. That means your landing page can be policy-dead even where the bottle itself is a lawful dietary supplement.

Meta adds a separate media-buying constraint. Its Drugs and Pharmaceuticals standard says "promoting prescription drugs is not allowed without authorization from Meta," with eligibility tied to online pharmacies, telehealth providers, pharmaceutical manufacturers, and certification or internal review. Its Health and Wellness policy also requires dietary, health, weight-loss, or weight-gain ads to target adults 18 or older, and bars certain appearance-negative and clickbait constructions.

This is where effective Facebook ad examples can mislead if you copy the surface and miss the policy class. The same visual grammar that works for general wellness can become a health-personal-attributes problem when the ad implies it knows the viewer's condition, weight problem, prescription use, or failed treatment history.

what makes this niche harder than it looks?

The niche is hard because the search demand is generated by a prescription drug, while many direct-response offers want supplement economics. That mismatch creates the margin temptation and the compliance trap in the same place. The stronger the semaglutide association, the better the click may look and the worse the claim file becomes.

FDA has already warned that retatrutide and cagrilintide cannot be used in compounding under federal law because they are not components of FDA-approved drugs and have not been found safe and effective for any condition. FDA also states there is no lawful basis for compounding semaglutide sodium or semaglutide acetate salt forms. Those are not copy-editing problems; they are product-status problems, and no VSL structure fixes them.

The second hard part is that platform review and regulator review do not ask the same question. Meta may reject for personal attributes, Google may suspend for circumventing systems, FDA may classify the product as an unapproved new drug, and FTC may attack the proof, reviews, or billing flow. Your campaign can pass one gate and still fail the next. We checked platform policy separately for that reason, because media buyers often collapse all risk into "will it approve?"

The workable path is narrower but cleaner: decide whether you are selling prescription access, a compounded drug, a research chemical, or a supplement, then write claims that match that product class. If the offer is actually a peptide supply question, best peptides supplier is the adjacent due-diligence problem, but it does not change the semaglutide advertising ceiling.

• Do not use competitor survival as proof of permission.
• Do not let the VSL claim what the label avoids.
• Do not treat a disclaimer as stronger than intended-use evidence.
• Do not price media before pricing refunds, testing, fulfillment, and review risk.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Nutra niche intelligence directory, FDA Rules the Label. FTC Rules Your Ad., 'Better Than the Injection' Is a Disease Claim, Cartilage Function Is Allowed. Joint Pain Is Not., Toothpaste Has No Structure/Function Safe Harbor, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.